What is amyloid light chain (AL) #amyloidosis? Learn more about this #RareDisease below. Amyloid light chain (AL) #amyloidosis, also referred to as AL, is a rare, systemic and progressive disorder caused by defective plasma cell in the bone marrow.

We’re committed to advancing the understanding of paroxysmal nocturnal haemoglobinuria (#PNH) and showing our support for the PNH community. Learn about this rare, chronic, progressive and potentially life-threatening blood disorder below.

Our mission is to transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that we do. Learn more our unwavering commitment to the #RareDisease community: alexion.com/about-us

Navigating the complex regulatory environment for #RareDisease requires innovation thinking and collaboration. Learn how we’re paving regulatory pathways using a patient-first mindset: alexion.com/news-centre-re…

We’re excited to be at the Endocrine Society’s Annual Meeting in Endocrinology presenting new research in #Hypophosphatasia (HPP) that could help improve understanding of this rare disease for endocrine and bone metabolism researchers and clinicians from around the globe.

Symptoms of hypophosphatasia (#HPP) can appear at any age and accumulate or worsen over time, they can cause significant disability or impaired mobility.

Developing transformative therapies for rare diseases means overcoming unique challenges and reimagining foundational elements of research and development. Learn more about Alexion's Research and Development: alexion.com/rare-disease-r…

Rare Connections in gMG sheds light on the emotional and physical toll of generalised #MyastheniaGravis (gMG) through the voices of three individuals living with gMG. Watch the film at spr.ly/60134qI1L to learn about the strength and resilience of Marta, Deanna and Nick.

Apply to join our talented team of individuals looking to make a difference in the lives of #RareDisease patients: careers.alexion.com

aHUS is a type of thrombotic microangiopathy (TMA), a group of severe and potentially life-threatening rare disorders that cause blood clots and damage to blood vessels, which can lead to organ damage and death. See the signs, symptoms & complications associated with TMAs⬇️

Dive into our research and development approach at Alexion, where science meets dedication to address rare diseases. Read more: alexion.com/our-approach

Pioneering innovation means being willing to push the boundaries of science to address areas of high unmet need. Learn more about this philosophy from Gianluca and how Alexion’s patient-centered approach is innovating rare disease clinical trial design. spr.ly/60184q4ru

At Alexion, we’re fueled by one purpose: to transform the lives of people living with #RareDiseases. Does this sound like you? Apply today: careers.alexion.com

Meet our diagnostics team working to advance the field to improve outcomes in #RareDisease.

#ICYMI: we launched Rare Connections in gMG to showcase the impact of generalised #MyastheniaGravis − a rare, often invisible, disease − on three people living with this condition. Click below to learn about the power that comes with being seen 👇 spr.ly/6019fuQDW

For many people, amyloid light chain (AL) #amyloidosis is not accurately diagnosed until the later stages of the disease, when prognosis is poor. Education around signs and symptoms is critical to help shorten time to diagnosis for patients.

Our mission is to transform the lives of people affected by rare diseases and devastating conditions by continuously innovating and creating meaningful value in all that we do. Learn more about who we are at Alexion, AstraZeneca #RareDisease: spr.ly/6014fkOs4

What makes regulatory affairs a unique group in rare disease R&D? Watch to learn more from Sarah Rhee.

Like many #RareDiseases, symptoms of generalised #MyastheniaGravis (gMG) can easily masquerade as many disorders, often delaying diagnosis for years to come. Recognising these symptoms can lead to faster diagnoses and help ensure the best possible outcomes.

Symptoms of hypophosphatasia (#HPP) can appear at any age and accumulate or worsen over time, they can cause significant disability or impaired mobility.